key: cord-0730485-m3m3t4oy authors: Breugelmans, J. Gabrielle; Zucs, Phillip; Porten, Klaudia; Broll, Susanne; Niedrig, Matthias; Ammon, Andrea; Krause, Gérard title: SARS Transmission and Commercial Aircraft date: 2004-08-03 journal: Emerg Infect Dis DOI: 10.3201/eid1008.040093 sha: c9877ae6ac5465d45291db9429e8e2b0976c8c48 doc_id: 730485 cord_uid: m3m3t4oy nan toms of SARS, including fever and general malaise developed; whether he had a cough at this time is unclear. He was admitted to a hospital in Hong Kong on April 8, and mechanical ventilation was initiated. He was reported to WHO as a suspected SARS patient on April 9 and diagnosed with SARS on April 10. Polymerase chain reaction analysis conducted on the patient's nasopharyngeal aspirate showed positive results for SARS-CoV on April 14. Passenger manifests from the seven flights on which the patient had flown were requested by the local health departments and the Institute. In a previous study, Kenyon et al. indicated that airline passengers seated within two rows of an infectious tuberculosis patient were at greatest risk for infection (4) . To determine an association between seating proximity to the SARS patient and transmission of SARS, a study that included all airline passengers seated within four rows (i.e., front, back, and same row) of the index patient (4) was conducted. Passengers ≥18 years of age who lived in Germany were contacted by the Institute and asked to participate in the study; all participants gave informed consent for inclusion in the study. Passengers in other countries were not included in the study because contact information was not available. Passengers <18 years of age were not included in the study; ethical approval from an Institutional Review Board, which would have delayed the study, would have been necessary. Contact information for study participants was forwarded to local health departments so that public health officials could provide follow-up care. Study participants were interviewed approximately 3 months after their flights because contact information was not available earlier. A standardized questionnaire was developed to collect information on demographics, flight details, countries visited before the flights, use of mask, and symptoms. Furthermore, 5-10 mL of whole blood was drawn and tested for SARS-CoV antibodies by using immunofluorescence assay. A total of 250 passengers were identified and selected for the study. Contact information was available for 109 passengers; 69 of the 109 were living in Germany. Sixty-two of those 69 passengers were contacted, and 41 passengers agreed to participate in the study. Thirty-six participants completed questionnaires and had blood samples taken. The male-to-female ratio was 3:5, and the median age was 41 years (25-59 years). Contact information was not available for five passengers, which made their inclusion in the study impossible. All serologic samples (N = 36) tested were negative for SARS-CoV immunoglobulin G antibodies, and none of the 36 passengers reported symptoms characteristic of SARS. Ten passengers complained of cough, headache, and muscle aches. One passenger reported a cough, muscle aches, and fever, but symptoms started 10 days after the flight. An analysis of the seating arrangement showed that the study participants were randomly distributed around the index patient. No SARS transmission was shown among contacted passengers seated in close proximity to the index patient; these results suggest that in-flight transmission of SARS is not common. These results are consistent with other studies that assessed the risk for inflight transmission of SARS (5, 6) . The results also suggest that SARS-CoV is not efficiently transmitted, as reflected in its basic reproduction number R 0 (range 2-4) (7). The SARS-infected patient on the indicated flights was in his first week of illness; infectivity is greatest in the second week (8) . Therefore, the likelihood of SARS transmission on the indicated flights was not high. These results are further supported by the fact that all contacts were asymptomatic 13 days after their last contact with the SARS patient. No information was available on healthcare contacts. Although we did not observe any SARS transmission, we cannot rule out the possibility that it may have occurred. We had no contact information on 56% of the passengers on the indicated flights and, therefore, had to exclude them from the investigation. Obtaining complete contact information from the remaining passengers was difficult, which severely impeded the investigation. Similarly, we were unable to contact crew members and had to exclude them. Recent studies have documented SARS transmission to passengers seated more than four rows away from an index patient (5, 9) ; thus, studying the passenger proximity to the patient may not be sufficient. Because of these limitations, our final sample size was small and probably biased. Since we did not observe any evidence to indicate in-flight transmission of SARS, we were unable to assess the importance of seat assignment proximity as a risk factor. The study shows that the roles of public health authorities and the aviation industry should be to "harmonise the protection of public health without the need to avoid unnecessary disrup-tion of trade and travel" in public health emergencies such as global SARS transmission (10) . We recommend strengthening the collaboration between national health authorities and the airline industry. Furthermore, the International Air Transport Association should establish procedures to ensure that complete contact information is available for all passengers and that rapid notification can be accomplished in case of potential exposure to infectious diseases. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area Severe acute respiratory syndrome: clinical outcome and prognostic correlates Identification of a novel coronavirus in patients with severe acute respiratory syndrome Transmission of multidrugresistant Mycobacterium tuberculosis during a long airplane flight Transmission of the severe acute respiratory syndrome on aircraft Low risk of transmission of severe acute respiratory syndrome on airplanes: the Singapore experience Directly transmitted infectious diseases: control by vaccination World Health Organization. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS) Introduction of SARS in France Global crisesglobal solutions. Managing public health emergencies of international concern through the revised international health regulations We thank René Gottschalk and Angela Wirtz for supporting negotiations with the airline; Bettina Supthut for data collection on all study participants in Munich, Germany; and the staff of all participating state and local health departments in Germany and all participating airline passengers.The Robert Koch Institute supported this investigation. At the time of the study, all authors were employed by this institute. To the Editor: In a recent article, Meltzer described a simulation method to estimate the incubation period for patients infected with SARS with multiple contact dates (1). In brief, he assumed a uniform distribution of all possible incubation periods derived from these contact dates for each patient and randomly selected an incubation period from all contact dates for each patient to obtain a distribution of the incubation period for all 19 patients. The process is